论文部分内容阅读
目的:针对转移性乳腺癌患者采用多西他赛与卡培他滨联合用药的临床效果进行探析。方法:选取我院2012年2月至2013年7月期间收治的46例转移性乳腺癌,随机分为对照组和试验组。对照组患者采用多西他赛与表柔比星联合进行治疗,而试验组患者采用多西他赛与卡培他滨联合用药,比较两组患者的治疗效果与不良反应发生几率。结果:试验组患者的治疗效果明显高于对照组,试验组患者缓解总有效率为82.61%,对照组患者总有效率为47.83%,两组患者比较差异具有统计学意义,即P<0.05。同时试验组中共有5例患者出现不良反应,而对照组中共有13例患者发生不良反应。对照组患者的不良反应发生几率明显高于试验组,两组患者比较具有统计学差异,即P<0.05。结论:对于转移性乳腺癌采用多西他赛与卡培他滨联合用药具有显著效果,可以减少患者的不良反应。
Objective: To investigate the clinical effect of docetaxel combined with capecitabine in patients with metastatic breast cancer. Methods: Forty-six patients with metastatic breast cancer who were treated in our hospital from February 2012 to July 2013 were randomly divided into control group and experimental group. Patients in the control group were treated with docetaxel combined with epirubicin. Patients in the test group were treated with docetaxel and capecitabine, and the treatment effect and the incidence of adverse reactions were compared between the two groups. Results: The therapeutic effect of the experimental group was significantly higher than that of the control group. The total effective rate of the experimental group was 82.61% and that of the control group was 47.83%. The difference between the two groups was statistically significant (P <0.05). At the same time, a total of 5 patients in the test group showed adverse reactions, while 13 patients in the control group had adverse reactions. The incidence of adverse reactions in patients in the control group was significantly higher than that in the experimental group, with statistical difference between the two groups (P <0.05). Conclusion: The combination of docetaxel and capecitabine has a significant effect on metastatic breast cancer, which can reduce adverse reactions in patients.